Hadassah

Hadassah-Developed Autoimmune Disease Drug Proves Safe in Phase I Clinical Trial

Thursday, Aug 6 2015

A drug developed at the Hadassah Medical Organization to help modulate the effects of autoimmune diseases such as rheumatoid arthritis has proven safe in a Phase I clinical trial at Hadassah. Manufactured by Protalix BioTherapeutics of Carmiel, Israel, the drug, PRX-106, proved to activate T cells, which have a central role in maintaining a well-functioning immune system.

"The results are very exciting and encouraging,” reports Prof. Yaron Ilan of Hadassah’s Internal Medicine Department A and a specialist in immunology and liver disease. “PRX-106 has the potential to be an effective agent for numerous immune-mediated disorders."

This Phase I trial tested the safety and tolerability of PRX-106 in healthy volunteers. With three separate cohorts receiving different doses of the protein compound for five consecutive days, the results demonstrated that oral administration of PRX-106 is safe and well tolerated in all three doses. In addition, researchers observed that PRX-106 triggered the action of various subsets of T cells, some of which are correlated with an anti-inflammatory response.

Preclinical studies with PRX-106 proved to alleviate both immune-mediated hepatitis and colitis in a mouse model, enhancing serum levels of regulatory T-cells and significantly improving clinical arthritis parameters, such as joint inflammation, swelling, and tissue degradation.

PRX-106 uses plant cells as a natural capsule for this protein compound. Protaliz anticipates that it will initiate the next phase of clinical trials with patients at the end of the year.

Comments

From: Penny Ellis on December 5, 2017
Will this drug help people with Crihn's Disease?
From: Gila on September 10, 2015
Would this drug also be one that could be effective in treating Crohn's Disease patients? As is now true of the RA drugs that work with T cells and the autoimmune system? Which I now inject....the oral/pill form sounds much more tolerable considering my Dr. says I will need to continue my therapy for life!
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Thursday, Apr 18 2019

Hadassah Cardiac Specialist Recognized for Lifetime Achievement

Congratulations to Hadassah Medical Organization Prof. Emeritus Andre Keren upon receiving the Lifetime Achievement Award from the European Society of Cardiology’s Working Group on Myocardial and Pericardial Diseases.

READ MORE ›
alt_text

Thursday, Apr 18 2019

Hadassah’s Pollin Center Celebrates Five Years of Women’s Wellness Achievements

Longing to commemorate the early death of her daughter from cardiovascular disease, Irene Pollin established the Linda Joy Pollin Cardiovascular Wellness Center for Women at Hadassah Hospital Ein Kerem in 2013.

READ MORE ›
alt_text

Thursday, Apr 18 2019

Pre-clinical Study by Hadassah Neurologists Sheds Light on Major Player in Alzheimer’s Disease

While scientists know a vast amount about what can go wrong in a brain afflicted with Alzheimer’s disease, they also know very little about how our brains protect themselves from such injuries, reports Prof. Tamir Ben-Hur, head of the Division of Clinical Neurosciences at the Hadassah Medical Organization.

READ MORE ›
alt_text

Wednesday, Apr 17 2019

First in Israel: Hadasit Launches Medical Startup Accelerator with IBM

Hadasit, the Hadassah Medical Organization’s technology transfer company, has launched Israel’s first biotechnology hub within a medical center.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More